Aspira Women's Health Inc. SEC filings AWHL
Aspira Women's Health Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Aug 12, 2011. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Jul 15, 2026 (material agreement, new debt). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 29, 2026 | — |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 24, 2026 | Jun 17, 2026 |
| DEF 14A | Proxy statement | Apr 11, 2025 | Dec 31, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 31, 2025 | Mar 31, 2025 |
| DEFA14A | Additional proxy material | May 10, 2024 | — |
| DEFA14A | Additional proxy material | Apr 1, 2024 | — |
| DEF 14A | Proxy statement | Apr 1, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 4, 2023 | — |
| DEF 14A | Proxy statement | Mar 30, 2023 | — |
| PRE 14A | Preliminary proxy statement | Mar 20, 2023 | — |
| DEF 14A | Proxy statement | Dec 28, 2022 | Dec 28, 2022 |
| PRE 14A | Preliminary proxy statement | Dec 16, 2022 | Dec 16, 2022 |
| DEFA14A | Additional proxy material | May 11, 2022 | — |
| DEFA14A | Additional proxy material | May 2, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Apr 29, 2022 |
| DEFA14A | Additional proxy material | May 10, 2021 | — |
| DEF 14A | Proxy statement | May 7, 2021 | May 7, 2021 |
| DEFA14A | Additional proxy material | May 11, 2020 | — |
| DEFA14A | Additional proxy material | May 8, 2020 | — |
| DEF 14A | Proxy statement | Apr 27, 2020 | Apr 27, 2020 |
| DEF 14A | Proxy statement | May 9, 2019 | May 9, 2019 |
| DEF 14A | Proxy statement | May 11, 2018 | May 11, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 27, 2018 | Apr 26, 2018 |
| DEF 14A | Proxy statement | Apr 27, 2017 | Apr 27, 2017 |
| DEF 14A | Proxy statement | Apr 29, 2016 | Apr 29, 2016 |
| DEF 14A | Proxy statement | Apr 29, 2015 | Apr 28, 2015 |
| DEF 14A | Proxy statement | Apr 29, 2014 | Apr 29, 2014 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2014 | Apr 18, 2014 |
| DEFA14A | Additional proxy material | Dec 5, 2013 | — |
| DEF 14A | Proxy statement | Nov 12, 2013 | Nov 12, 2013 |
| PRE 14A | Preliminary proxy statement | Nov 1, 2013 | Oct 31, 2013 |
| DEFA14A | Additional proxy material | Mar 19, 2013 | — |
| DEFA14A | Additional proxy material | Mar 1, 2013 | — |
| DEFA14A | Additional proxy material | Feb 21, 2013 | — |
| DEFA14A | Additional proxy material | Feb 11, 2013 | — |
| DEFA14A | Additional proxy material | Jan 29, 2013 | — |
| DEF 14A | Proxy statement | Jan 28, 2013 | Mar 21, 2013 |
| DEFA14A | Additional proxy material | Nov 19, 2012 | — |
| DEFA14A | Additional proxy material | May 16, 2012 | — |
| DEFA14A | Additional proxy material | May 4, 2012 | — |
| DEFA14A | Additional proxy material | Mar 15, 2012 | — |
| DEFA14A | Additional proxy material | Mar 7, 2012 | — |
Showing 43 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- AWHL (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 926617
- Former names
- VERMILLION, INC. (until Jun 10, 2020); CIPHERGEN BIOSYSTEMS INC (until Aug 17, 2007)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.